# U.S. Patent 10,034,877: Linagliptin Renal-Impairment Claims, Scope, Expiration, and Patent Landscape

U.S. Patent No. 10,034,877 protects a narrow clinical use of linagliptin, the DPP-4 inhibitor marketed as Tradjenta. The core claims cover administering 5 mg of linagliptin once daily to patients with type 2 diabetes for whom metformin is inappropriate, including patients with mild, moderate, or severe renal impairment and end-stage renal disease, without reducing the linagliptin dose.

The patent is a method-of-use patent. It does not broadly claim linagliptin as a molecule, a tablet formulation, or every use of linagliptin in diabetes. Its commercial significance depends on whether a competing product is labeled, promoted, or used for the renal-impaired, metformin-ineligible population.

What drug and therapeutic use does U.S. Patent 10,034,877 cover?

The claimed active ingredient is linagliptin, chemically identified in the claims as:

1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine.

Linagliptin is an orally administered DPP-4 inhibitor approved by the FDA for improving glycemic control in adults with type 2 diabetes mellitus. The approved dose is 5 mg once daily, and the FDA labeling states that no renal dose adjustment is required.[1]

The patent targets a specific clinical problem: metformin is commonly used as initial therapy for type 2 diabetes but may be contraindicated or unsuitable in patients with renal disease, renal dysfunction, metabolic acidosis, or certain other conditions. The claimed approach uses linagliptin as a 5 mg daily treatment without the renal dose reductions required for several competing antidiabetic agents.

What are the independent claims of U.S. Patent 10,034,877?

The patent contains four principal independent claims: claims 1, 12, 13, and 15.

Claim	Core subject matter	Patient population	Dose requirement
1	Treatment of metabolic disease when metformin is inappropriate	Metformin contraindication, including renal disease, heart failure, acidosis, or hereditary galactose intolerance	5 mg orally per day; no adjustment across renal impairment categories
12	Treatment of type 2 diabetes	Metformin inappropriate because of renal disease, renal impairment, renal dysfunction, or metabolic acidosis	5 mg daily; no adjustment
13	Treatment of type 2 diabetes	Severe renal impairment or end-stage renal disease	5 mg daily; no adjustment
15	Treatment of type 2 diabetes in a renally impaired patient	Metformin contraindicated because of renal impairment	Same daily dose as for normal renal function

Claim 1 is the broadest independent claim in disease scope because it covers “metabolic diseases,” rather than only type 2 diabetes. Claims 12, 13, and 15 are narrower but more directly aligned with the commercial labeling and the patent’s renal-impairment rationale.

How narrow is the core claim scope?

The claims require the concurrence of several limitations:

The patient has a metabolic disease, generally type 2 diabetes.
Metformin therapy is inappropriate, contraindicated, or unsuitable.
The contraindication falls within a specified category.
Linagliptin is administered orally.
The dose is 5 mg per day.
No dose adjustment is made for renal impairment, including end-stage renal disease.

A product containing linagliptin does not automatically infringe the patent merely because it is sold at a 5 mg dose. The relevant question is whether the accused conduct falls within the claimed patient population and treatment method.

The most important limitations are the metformin-related condition and the renal dosing limitation. A generic manufacturer could attempt to avoid direct infringement by seeking a label that omits the patented renal-impaired or metformin-ineligible use. That strategy would need to be assessed against the actual FDA label, prescribing information, promotional conduct, physician instructions, and induced-infringement evidence.

What renal impairment populations are protected?

The claims expressly reach:

Mild renal impairment
Moderate renal impairment
Severe renal impairment
End-stage renal disease
Renal disease
Renal dysfunction

Claims 7, 13, and 16 concentrate on severe renal impairment and end-stage renal disease. Claim 6 is particularly important because it requires the same linagliptin dose for patients with renal impairment as for patients with normal renal function.

The no-adjustment limitation is affirmative. The claim is directed to administering 5 mg without reducing the dose, rather than merely administering linagliptin to a patient who happens to have renal impairment. A regimen using a reduced dose may fall outside these claims, although it could implicate other patent claims or patents.

The FDA label supports the clinical premise. For Tradjenta, the FDA states that no dose adjustment is needed in patients with renal impairment, including those receiving dialysis.[1]

What combination therapies are covered?

Claims 8 through 11 extend the method to combination treatment. The additional agent may be selected from broad categories of antidiabetic, lipid-lowering, blood-pressure-lowering, anti-atherosclerotic, or anti-obesity therapies.

Claim 9 identifies several antidiabetic classes:

Sulfonylureas
Thiazolidinediones
Glinides
Alpha-glucosidase inhibitors
GLP-1 and GLP-1 analogues
Insulin and insulin analogues

Claim 10 narrows the combinations to repaglinide, pioglitazone, and insulin or insulin analogues. Claim 11 specifically claims linagliptin with pioglitazone.

These claims could be relevant to combination products, co-packaged products, or prescribing instructions that direct use of linagliptin with another antidiabetic. They do not necessarily cover every product containing a second active ingredient. The underlying patient, metformin contraindication, 5 mg dose, and no-dose-adjustment limitations from claim 1 remain incorporated.

What is the legal significance of claim 15?

Claim 15 appears to contain a chemical-name drafting error. It identifies the active ingredient as:

1-[(4-methyl-quinazolin-2-yl)-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine.

Unlike claim 1, the text omits the apparent “methyl” linkage after “quinazolin-2-yl.” As written, the chemical name is grammatically and structurally inconsistent with linagliptin.

The error does not automatically invalidate claim 15. Courts generally interpret claims in the context of the specification, prosecution history, and the patent as a whole. A court could determine that the omission is an obvious typographical error and correct it if the intended correction is not subject to reasonable dispute. Alternatively, the defect could create indefiniteness or scope disputes if the claim cannot be construed with reasonable certainty.

Claims 1, 12, and 13 do not appear to depend on the same wording defect. They provide potentially stronger enforcement positions for the renal-impaired use.

What are the dependent claims worth commercially?

The dependent claims divide into three commercial groups.

Metformin-ineligible patients

Claims 2 and 3 clarify that the patient may be ineligible for metformin or may require a reduced metformin dose because of a contraindication. These claims reinforce the treatment-substitution theory but do not materially broaden claim 1.

Type 2 diabetes and renal impairment

Claims 4 through 7 narrow the disease and contraindication to type 2 diabetes and renal dysfunction. These claims correspond closely to the real-world use of Tradjenta in patients with chronic kidney disease.

Combination therapy

Claims 8 through 11 cover add-on or combination regimens. Claim 11, covering linagliptin with pioglitazone, is the narrowest and most readily testable combination claim.

What patents protect linagliptin besides U.S. Patent 10,034,877?

Linagliptin’s patent estate has several layers:

Patent layer	Typical protection	Strategic purpose
Compound patents	Linagliptin and related xanthine compounds	Protect the active pharmaceutical ingredient
Salt and crystal-form patents	Solid forms, crystalline linagliptin, salts	Restrict alternative API presentations
Formulation patents	Tablets, excipients, dissolution, stability	Protect commercial dosage forms
Combination patents	Linagliptin with metformin or other antidiabetics	Protect fixed-dose and add-on products
Method-of-use patents	Type 2 diabetes, renal impairment, metformin-ineligible patients	Protect prescribing populations and dosing regimens
Manufacturing patents	Synthetic intermediates and processes	Increase switching costs and limit non-infringing API routes

Boehringer Ingelheim and related entities developed and commercialized linagliptin. Eli Lilly participated in the original commercialization relationship for Tradjenta before Boehringer assumed broader commercialization responsibilities in several markets.[2]

The principal compound patent family for linagliptin is distinct from U.S. Patent 10,034,877. A challenge to this patent would not necessarily eliminate compound, formulation, or process barriers.

When does U.S. Patent 10,034,877 expire?

The patent issued on July 31, 2018.[3] The relevant patent term is generally calculated from the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers, and any applicable patent-term extension.

Public patent records identify the family as directed to the use of linagliptin in patients with renal impairment and related metformin contraindications. The expected base term is in the late 2020s, with the exact enforceable date dependent on the recorded patent-term adjustment and any terminal disclaimer. The USPTO Patent Center record is the controlling source for the final term calculation.[4]

Because this is a use patent, its expiration date should be evaluated separately from:

The expiration of the linagliptin compound patent
FDA regulatory exclusivity
Any pediatric exclusivity
Other listed formulation or combination patents

What is the Orange Book status of U.S. Patent 10,034,877?

A method-of-use patent may be listed in the FDA Orange Book if it claims an approved method of using the drug. Orange Book listing is commercially significant because an ANDA applicant must address listed patents through a Paragraph I, II, III, or IV certification.[5]

For an NDA product such as Tradjenta, a generic applicant could confront:

A Paragraph III certification stating that the applicant will wait until patent expiration
A Paragraph IV certification asserting that the patent is invalid, unenforceable, or not infringed
A section viii statement carving out a patented method of use, if the FDA-approved labeling permits a lawful carve-out

The practical question is whether the patent is listed against Tradjenta and whether its renal-impaired use appears in the corresponding FDA-approved labeling. The Orange Book and FDA patent-listing records, rather than the patent document alone, control the regulatory analysis.[5]

What Paragraph IV challenges and litigation risks exist?

A Paragraph IV challenge to this patent would likely focus on four issues.

Inherency and anticipation

The challenger could argue that prior art already disclosed linagliptin 5 mg once daily for type 2 diabetes and that renal impairment or metformin contraindication was an inherent or predictable patient characteristic. The patentee would argue that the claimed no-adjustment renal regimen and metformin-ineligible population were not disclosed as a treatment method.

Obviousness

The challenger could combine prior art concerning:

Linagliptin’s DPP-4 mechanism
Its 5 mg dose
Renal pharmacokinetics
The clinical limitations of metformin
The absence of a need for renal dose adjustment

The patentee’s strongest response would likely rely on the specific clinical finding that linagliptin could be used at the same 5 mg dose across renal-function categories.

Written description and enablement

The claims cover broad categories, including multiple renal impairment levels and numerous combination therapies. A challenge could argue that the specification does not adequately support every claimed patient category or combination. The risk is higher for the broad combination language in claims 8 and 9 than for the core 5 mg renal dosing claims.

Indefiniteness and claim error

Claim 15’s apparent chemical-name omission creates a focused construction issue. Claims 1, 12, and 13 may be less exposed because they identify the active ingredient more completely.

No litigation conclusion should be drawn solely from the patent number. A current case search must include PACER, district-court dockets, the Federal Circuit, PTAB proceedings, and FDA Paragraph IV notices.

How strong is the patent estate for linagliptin?

The estate is strongest when viewed as a layered portfolio rather than through U.S. Patent 10,034,877 alone.

Risk area	Relative strength	Reason
Compound protection	High historically	Direct API protection creates the clearest infringement theory
Renal dosing use	Moderate to high	Closely aligned with the FDA label and a specific clinical advantage
Metformin-contraindication use	Moderate	Requires proof of patient eligibility and treatment purpose
Broad combination claims	Moderate	Breadth increases validity and written-description exposure
Claim 15	Lower	Apparent chemical-name drafting defect
Formulation protection	Product-specific	Depends on separate formulation patents and the accused dosage form
Manufacturing protection	Route-specific	Depends on the process used by the API supplier

The patent is commercially relevant even if compound protection has expired or is approaching expiry. A generic applicant may need to design a label around the renal-impaired use or accept litigation risk based on induced infringement.

What generic launch scenarios exist?

Three launch paths are most relevant.

Full-label launch after patent expiry

The generic applicant includes the renal-impaired and metformin-ineligible uses after the relevant listed patent expires. This is the lowest regulatory-risk scenario.

Section viii skinny label

The applicant removes the patented renal-use indication if the FDA permits the carve-out and the remaining label is commercially viable. This approach reduces direct label-based infringement risk but does not eliminate induced-infringement exposure from marketing or physician instructions.

Paragraph IV challenge

The applicant certifies that the patent is invalid, unenforceable, or not infringed. A Paragraph IV notice would create Hatch-Waxman litigation risk and could trigger a 30-month stay of final ANDA approval under the statutory framework, subject to the specific procedural record.[6]

How does linagliptin compare with competing DPP-4 inhibitors?

Linagliptin’s renal dosing position is commercially distinctive.

DPP-4 inhibitor	General renal dosing position
Linagliptin	5 mg once daily without renal dose adjustment
Sitagliptin	Dose reduction required with moderate or severe renal impairment
Saxagliptin	Dose reduction required in renal impairment
Alogliptin	Dose reduction required in moderate or severe renal impairment
Vildagliptin	Dose adjustment or restrictions may apply by jurisdiction

This distinction supports the patent’s technical rationale and the product’s positioning in patients with chronic kidney disease. It does not, by itself, prove patent validity. Clinical differentiation and patent scope remain separate questions.

What FDA regulatory status applies to the claimed use?

The claimed active ingredient is FDA-approved as linagliptin for adults with type 2 diabetes, as monotherapy or in combination with other glucose-lowering agents, including insulin.[1] The FDA-approved dose is 5 mg once daily. The label states that no dose adjustment is required for renal impairment.

The patent’s references to hereditary galactose intolerance and some combination categories may extend beyond the precise current label for a particular linagliptin product. Regulatory relevance must therefore be tested against the approved indication and labeling in force when the patent is asserted.

Key Takeaways

U.S. Patent 10,034,877 is a linagliptin method-of-use patent.
Its central protection is 5 mg oral linagliptin once daily for type 2 diabetes patients who cannot appropriately receive metformin.
Renal impairment and end-stage renal disease are the most commercially important populations.
The claims require no renal dose adjustment, which tracks the Tradjenta FDA label.
Claims 8 through 11 cover combination therapy, including pioglitazone and insulin.
Claim 15 contains an apparent chemical-name drafting defect that could create a claim-construction dispute.
The patent must be analyzed alongside compound, formulation, combination, process, and other method-of-use patents.
Generic entry may occur through patent expiry, a section viii label carve-out, or a Paragraph IV challenge.
Orange Book listing and current patent-term data should be verified from FDA and USPTO records before relying on an exact launch date.

FAQs

Does U.S. Patent 10,034,877 cover all linagliptin products?

No. It covers specified treatment methods. A linagliptin product may fall outside the patent if it is not used for the claimed metformin-ineligible or renally impaired population, although other patents may apply.

Does the patent cover linagliptin use in dialysis patients?

Claims 1, 7, 13, and related claims expressly reach end-stage renal disease. The FDA label also states that no dose adjustment is required in renal impairment, including dialysis patients.[1]

Can a generic company omit the renal indication from its label?

Potentially, through a section viii carve-out, if the FDA permits the omission and the remaining labeling remains approvable. The carve-out does not eliminate all possible induced-infringement theories.

Is linagliptin’s 5 mg dose itself patent-protected by this patent?

The 5 mg dose is protected only when combined with the other claim limitations, including the patient’s metformin contraindication and the absence of renal dose adjustment. The patent does not claim every administration of 5 mg linagliptin.

Does the apparent error in claim 15 invalidate the entire patent?

No. Any defect in claim 15 would ordinarily be analyzed claim by claim. The enforceability of claims 1, 12, and 13 would not automatically depend on the construction of claim 15.

References

U.S. Food and Drug Administration. (2023). Tradjenta (linagliptin) prescribing information.
Boehringer Ingelheim Pharmaceuticals, Inc. (2011). Tradjenta FDA approval and product information.
U.S. Patent and Trademark Office. (2018). U.S. Patent No. 10,034,877, Treatment of diabetes mellitus in patients for whom metformin therapy is inappropriate.
U.S. Patent and Trademark Office. (n.d.). Patent Center: U.S. Patent No. 10,034,877.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
21 U.S.C. § 355(j); 35 U.S.C. § 271(e).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Boehringer Ingelheim	TRADJENTA	linagliptin	TABLET;ORAL	201280-001	May 2, 2011	AB	RX	Yes	Yes	10,034,877*PED	⤷ Start Trial			Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	072920	⤷ Start Trial
Australia	2009279085	⤷ Start Trial
Brazil	PI0916997	⤷ Start Trial
Canada	2732803	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,034,877

Which drugs does patent 10,034,877 protect, and when does it expire?

Summary for Patent: 10,034,877